Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

81.38 -1.13 (-1.37%)
Streaming Delayed Price Updated: 10:35 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout ↗
Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors. 
Via Chartmill
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗
Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential. 
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Tarsus Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗
Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase 
Via The Motley Fool
News headline image
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
3 Biotech Catalysts Present Major Opportunity ↗
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗
 
Via Benzinga
News headline image
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
News headline image
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick? ↗
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS). 
Via Chartmill
News headline image
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) ↗
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). 
Via Chartmill
News headline image
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.